Drugs / GD2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00045617 | Jan → May 2003 | lung cancer | SWOG Cancer Research Network | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GD2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00045617 ↗ |
| Known as | TriGem | “Patients also receive monoclonal antibody 11D10 anti-idiotype vaccine (TriAb) and monoclonal antibody GD2 anti-idiotype vaccine (TriGem) intradermally on day 1 of weeks 11, 13,...” NCT00045617 ↗ |
| Modality | Vaccine | “monoclonal antibody GD2 anti-idiotype vaccine” NCT00045617 ↗ |
| Route | Other | “Patients also receive monoclonal antibody 11D10 anti-idiotype vaccine (TriAb) and monoclonal antibody GD2 anti-idiotype vaccine (TriGem) intradermally on day 1 of weeks 11, 13,...” NCT00045617 ↗ |
| Route | Subcutaneous | “Patients also receive monoclonal antibody 11D10 anti-idiotype vaccine (TriAb) and monoclonal antibody GD2 anti-idiotype vaccine (TriGem) intradermally on day 1 of weeks 11, 13,...” NCT00045617 ↗ |